Skip to main content

RECIST underestimates benefit of pembrolizumab in subset of melanoma patients

Primary tabs

View
Get Stamp Tags
Published Locations

Breadcrumb

Home
RECIST underestimates benefit of pembrolizumab in subset of melanoma patients

User login

Username

Password

Reset your password

Type	Lead	score